Saba Capital Amends abrdn Life Sciences Investors (HQL) 13D Filing
Ticker: HQL · Form: SC 13D/A · Filed: Jan 12, 2024 · CIK: 884121
| Field | Detail |
|---|---|
| Company | Abrdn Life Sciences Investors (HQL) |
| Form Type | SC 13D/A |
| Filed Date | Jan 12, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $22,413,093 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: activist-investing, amendment, insider-activity
TL;DR
**Saba Capital just updated its activist stake in abrdn Life Sciences Investors, watch for potential moves!**
AI Summary
Saba Capital Management, L.P. filed an amended Schedule 13D/A on January 12, 2024, updating its beneficial ownership in abrdn Life Sciences Investors. This amendment, dated January 10, 2024, indicates a change in their holdings or intentions regarding the common shares of abrdn Life Sciences Investors. For shareholders, this matters because Saba Capital Management is an activist investor, and changes in their filings can signal potential future actions like advocating for corporate changes or adjusting their investment strategy, which could impact the stock's value.
Why It Matters
This filing signals that a significant activist investor, Saba Capital Management, has updated its position or intentions regarding abrdn Life Sciences Investors, potentially foreshadowing future strategic moves that could influence the company's direction and stock performance.
Risk Assessment
Risk Level: medium — The involvement of an activist investor like Saba Capital can lead to significant corporate changes, which can be either beneficial or detrimental to existing shareholders.
Analyst Insight
Investors should monitor future filings from Saba Capital Management regarding abrdn Life Sciences Investors for any significant changes in ownership percentage or stated intentions, as these could signal upcoming activist campaigns or strategic shifts that may impact the stock price.
Key Numbers
- $0.01 — par value per common share (identifies the nominal value of abrdn Life Sciences Investors' common shares)
- 87911K100 — CUSIP Number (unique identifier for abrdn Life Sciences Investors' common shares)
Key Players & Entities
- Saba Capital Management, L.P. (company) — the filing person and activist investor
- abrdn Life Sciences Investors (company) — the subject company whose securities are being reported
- Boaz R. Weinstein (person) — a group member associated with Saba Capital Management
- Saba Capital Management GP, LLC (company) — a group member associated with Saba Capital Management
- Michael D'Angelo (person) — contact person for Saba Capital Management, L.P.
Forward-Looking Statements
- Saba Capital Management will continue to be an active shareholder in abrdn Life Sciences Investors. (Saba Capital Management, L.P.) — high confidence, target: 2025-01-12
- The filing indicates a potential shift in Saba Capital's strategy or holdings, which could lead to further public announcements or actions. (abrdn Life Sciences Investors) — medium confidence, target: 2024-07-12
FAQ
Who filed this SC 13D/A amendment?
Saba Capital Management, L.P. filed this SC 13D/A amendment, as indicated in the 'FILED BY' section and the cover page of the filing.
What is the subject company of this filing?
The subject company is abrdn Life Sciences Investors, as stated under 'SUBJECT COMPANY' and 'Name of Issuer' on the cover page.
What is the date of the event that required this filing?
The date of the event which required this filing is January 10, 2024, as specified on the cover page of the Schedule 13D/A.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Shares, $0.01 par value, of abrdn Life Sciences Investors is 87911K100, as listed on the cover page.
What was the former name of abrdn Life Sciences Investors?
abrdn Life Sciences Investors was formerly known as TEKLA LIFE SCIENCES INVESTORS until October 15, 2014, and before that, H&Q LIFE SCIENCES INVESTORS until September 29, 1992, according to the 'FORMER COMPANY' section of the filing.
Filing Stats: 1,307 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2024-01-12 11:41:22
Key Financial Figures
- $0.01 — stors (Name of Issuer) Common Shares, $0.01 par value (Title of Class of Securities
- $22,413,093 — ported herein. A total of approximately $22,413,093 was paid to acquire the Common Shares r
Filing Documents
- formsc13da.htm (SC 13D/A) — 52KB
- 0001062993-24-000825.txt ( ) — 54KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: January 12, 2024 SABA CAPITAL MANAGEMENT, L.P. By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Chief Compliance Officer SABA CAPITAL MANAGEMENT GP, LLC By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Authorized Signatory BOAZ R. WEINSTEIN By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Attorney-in-fact* * Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823 CUSIP No. 87911K100 SCHEDULE 13D/A Page 7 of 7 Pages Schedule A This Schedule sets forth information with respect to each purchase and sale of Common Shares which were effectuated by Saba Capital since the filing of the Schedule 13D/A on 12/29/23. All transactions were effectuated in the open market through a broker. Trade Date Buy/Sell Shares Price 1/2/2024 Buy 9,918 13.71 1/3/2024 Buy 34,902 13.75 1/4/2024 Buy 20,089 13.85 1/8/2024 Buy 42,454 13.89 1/9/2024 Buy 19,147 14.24 1/9/2024 Buy 100,000 14.25 1/10/2024 Buy 108,717 14.27